34048-57-2

Usage

Uses

Used in Perfumery and Flavoring Industry:
(1R,2S,5R)-(-)-Menthyl amine is used as a fragrance ingredient and flavoring agent for its characteristic minty scent, adding a refreshing quality to perfumes and enhancing the taste of food products.
Used in Pharmaceutical Industry:
(1R,2S,5R)-(-)-Menthyl amine is used as a potential therapeutic agent due to its antiviral and anti-inflammatory properties, offering new avenues for the development of medications to treat various diseases.
Used in Organic Chemical Synthesis:
(1R,2S,5R)-(-)-Menthyl amine serves as a reagent in organic synthesis, facilitating the production of various chemical compounds and contributing to the advancement of chemical research and development.

Upstream product

• 2216-54-8 L-menthylamine 
• 10458-14-7 (2R,5S)-menthone 
• 65620-72-6 (1R,5S)-menthone oxime 
• 39633-53-9 (-)-(1R,3R,4S)-menthyl isocyanate 

Downstream Products

• 139680-35-6 d-Menthyl-α-fluoracrylamid 
• 56087-03-7 salicylidene-L-menthylamine 
• 108181-68-6 N,N'-Bis(menthyl)-hexan-2,5-diimin 
• 2216-51-5 (-)-menthol 
• 619-52-3 (1R)-menth-3-ene 
• 1228639-09-5 N-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oleamide 
• 1228639-14-2 N-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]-7-phenylheptanamide 
• 1228639-16-4 N-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]-8-phenyloctanamide 
• 1228639-03-9 N-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]-4-methylbenzamide 
• 1228639-06-2 4-tert-butyl-N-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]benzamide 
• 1228639-20-0 N-[(1R, 2S, 5R)-2-isopropyl-5-methylcyclohexyl]-4-chlorobenzamide 
• 1228639-12-0 N-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)-[1,1'-biphenyl]-4-carboxamide 
• 39633-53-9 (-)-(1R,3R,4S)-menthyl isocyanate 
• 108194-62-3 4-N-Menthyl-pentanimin-2-on 

Relevant academic research and scientific papers

Synthesis of platinum complexes containing (+)-bornyl- and (-)-menthylammonium in the outer coordination sphere and their catalytic activity in hydrosilylation reactions

Optically active (+)-bornyl- and (-)-menthylammonium platinates were synthesized starting from H2[PtCl6] ? 4H2O and hydrochlorides of the corresponding amines. Catalytic activity of the complexes in the hydrosilylation reactions of 1,3-divinyl-1,1,3,3- tetramethyldisiloxane with 1,1,3,3-tetramethyldisiloxane and acetophenone with diphenylsilane was studied. The addition of the siloxanes leads to a predominant formation of β-adduct. Activity of the catalysts, evaluated on the 50% conversion of the substrate, decreases in the following sequence: (-)-(menthylNH3)2[PtCl6] > (Et 3NH)2[PtCl6] > (+)-(bornylNH 3)2[PtCl4] > (+)-(bornylNH3) 2[PtCl6]. Asymmetric induction is observed in the hydrosilylation of aceto-phenone in the presence of (+)-(bornylNH 3)2[PtCl n ] (n = 4, 6); (+)-(bornylNH 3)2[PtCl6] showed the highest catalytic activity and selectivity. The hydrosilylation of acetophenone gave 1-phenylethoxy(diphenyl)silane, 1-phenylvinyloxy(diphenyl)silane, and 2-phenylethyl-2-diphenylsiloxy(diphenyl)silane as the products.

Efficient and stereodivergent electrochemical synthesis of optically pure menthylamines

The cathode directs the way to the epimeric menthylamines. The reduction of menthone oxime on a Hg cathode generates (-)-menthylamine as the major product, whereas a Pb cathode gives access to (+)-neomenthylamine (see scheme). Insitu decoration of the Pb cathode by small amounts of additives results in clean and quantitative conversions. Furthermore, Pb corrosion is completely prevented in this practical method. Copyright

Compositions and methods for the treatment of disease associated with Trp-p8 expression

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.